



Keenan Pharmacy Services
San Joaquin Valley Insurance Authority
Quarterly Key Pharmacy Benefit Metrics
Data Reviewed Through: 2021 3rd Quarter

Presented by Alexandria Van Brunt
Sr. Account Manager, KPS

Quarterly Key Pharmacy Benefit Metrics

Executive Summary

Q3 2021 Highlights:

Q3 2021 Overall Plan Spend

- SJVIA's total plan cost increased in Q3 2021 by 4.18% from Q2 2021 to **\$5,284,412**
 - Tulare: \$2,160,996 in Plan Cost
 - Fresno: \$3,123,415 in Plan Cost
- The increase in plan spend can be attributed to utilization increasing, as well as inflation.
- There was an increase of 11% in plan cost when comparing Q3 2020 (\$4,761,678) to Q3 2021 (\$5,284,412).

Q3 Channel Summary

- Majority of the SJVIA members continue to fill scripts at retail.
 - Retail scripts account for 98.68% of plan spend.
- Overall, the claims volume in Q3 2021 increased in all channels apart from mail brand and generic.
 - Majority of scripts are being filled in the retail generic or retail90 generic channel.

Q3 Generic Dispensing

- The Generic Dispensing Rate Continues to trend well for SJVIA in all channels.
 - Although the GDR trends well, it did decrease slightly for Retail GDR, Retail90 GDR and Mail GDR in Q3 2021.
 - Q3 2021 Retail GDR: 82%
 - Q2 2021: 82.76%
 - Q3 2021 Retail90 GDR: 88.62%
 - Q2 2021: 89.09%
 - Q3 2021 Mail GDR: 86.39%
 - Q2 2021: 87.83%

Quarterly Key Pharmacy Benefit Metrics

Executive Summary Continued

Q3 2021 Specialty Plan Spend

- Q3 2021 specialty plan spend increased compared to previous quarters.
 - The spend shift can be mostly attributed to the specialty channel seeing a significant increase in utilization for Q3.
 - Specialty Plan Costs in Q3: \$2,113,192 (39.99% of plan spend)
 - Specialty Plan cost in Q2 2021: \$2,003,006
 - * There was an increase in specialty plan cost when comparing Q3 2021 (\$2,113,192) to Q3 2020 (\$1,471,204).
- Specialty claims volume increased with new utilization in Q3 2021.
 - 578 Scripts filed in Q3 2021.
 - 39 additional scripts compared to Q2 2021
 - 539 Scripts filed in Q2 2021
 - 77 additional scripts compared to Q3 2020
 - 491 Scripts filed in Q3 2020
 - SJVIA specialty plan costs trends above the EmpiRx BOB national average range (30%-35%).

Top clinical cost drivers by Therapeutic Class

- ANALGESICS - ANTI-INFLAMMATORY
- ANTIDIABETICS
- DERMATOLOGICALS
- ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
- RESPIRATORY AGENTS- MISC.
- ANTICOAGULANTS
- ANTIPSYCHOTICS/ANTIMANIC AGENTS

Quarterly Key Pharmacy Benefit Metrics

Executive Summary Continued

Top Clinical Cost Drivers by Drug (Q3 2021):


- HUMIRA PEN (ANALGESICS - ANTI-INFLAMMATORY)
 - 2021 (Q3) ingredient costs: \$697,541.19
 - 17 Utilizers (1 additional utilizers than Q2)
- TRULICITY (ANTIDIABETICS)
 - 2021 (Q3) ingredient costs: \$665,896.45
 - 113 Utilizers (12 additional utilizers than Q2)
- OZEMPIC (ANTIDIABETICS)
 - 2021 (Q3) ingredient costs: \$379,513.94
 - 91 Utilizers (19 additional utilizers than Q2)
- TREMFYA (DERMATOLOGICALS)
 - 2021 (Q3) ingredient costs: \$354,282.85
 - 9 Utilizers (1 additional utilizers than Q2)
- JARDIANCE (ANTIDIABETICS)
 - 2021 (Q3) ingredient costs: \$320,923.85
 - 96 Utilizers (12 additional utilizers than Q2)
- DUPIXENT (DERMATOLOGICALS)
 - 2021 (Q3) ingredient costs: \$314,157.96
 - 15 Utilizers (2 additional utilizers than Q2)
- JANUVIA (ANTIDIABETICS)
 - 2021 (Q3) ingredient costs: \$309,929.04
 - 107 Utilizers (10 additional utilizers than Q2)
- SPRYCEL (ANALGESICS - ANTI-INFLAMMATORY)
 - 2021 (Q3) ingredient costs: \$262,889.36
 - 2 Utilizers (no change in utilization from Q2)

***Specialty medications require a prior authorization before they can be filled.**

Quarterly Key Pharmacy Benefit Metrics

Cost Trend by Quarter

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Gross Cost	\$4,844,157	\$5,320,273	\$5,153,562	\$5,145,875	\$5,150,035	\$4,829,456	\$5,463,764	\$5,683,985
Plan Cost	\$4,472,131	\$4,893,192	\$4,763,678	\$4,761,468	\$4,769,527	\$4,443,378	\$5,072,541	\$5,284,412
Member Cost	\$372,026	\$427,081	\$389,883	\$384,407	\$380,507	\$386,078	\$391,223	\$399,573




- This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
- Gross cost = plan cost + member cost

Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Brand	\$1,162,594	\$1,252,574	\$1,186,673	\$1,204,674	\$1,213,904	\$1,148,357	\$1,130,608	\$1,193,251
Retail Generic	\$671,424	\$767,794	\$675,196	\$661,165	\$568,630	\$535,374	\$516,396	\$532,016
Retail90 Brand	\$819,714	\$901,044	\$886,199	\$915,081	\$928,860	\$885,454	\$938,130	\$978,312
Retail90 Generic	\$356,074	\$397,208	\$405,162	\$458,566	\$455,767	\$442,117	\$441,518	\$425,807
Mail Brand	\$35,685	\$35,378	\$22,627	\$32,105	\$22,821	\$22,095	\$21,536	\$24,463
Mail Generic	\$15,576	\$14,795	\$15,814	\$18,672	\$20,104	\$17,860	\$21,347	\$17,370
Specialty	\$1,411,065	\$1,524,399	\$1,572,007	\$1,471,204	\$1,559,440	\$1,392,121	\$2,003,006	\$2,113,192



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Brand	3,287	3,088	2,719	3,241	3,534	2,919	3,229	3,453
Retail Generic	17,630	19,950	16,006	16,724	15,856	15,364	15,496	15,730
Retail90 Brand	917	951	948	967	942	906	891	935
Retail90 Generic	6,565	7,190	7,025	7,196	7,191	7,123	7,275	7,279
Mail Brand	38	42	30	38	35	23	28	26
Mail Generic	184	175	204	184	178	185	202	165
Specialty	485	495	520	491	507	477	539	578



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Specialty Plan Cost	\$1,411,065	\$1,524,399	\$1,572,007	\$1,471,204	\$1,559,440	\$1,392,121	\$2,003,006	\$2,113,192
Total Plan Cost	\$4,472,131	\$4,893,192	\$4,763,678	\$4,761,468	\$4,769,527	\$4,443,378	\$5,072,541	\$5,284,412
Specialty Plan Cost %	31.55%	31.15%	33.00%	30.90%	32.70%	31.33%	39.49%	39.99%




- Specialty plan cost represents 39.99% of the SJVIA plan cost in Q3 2021
- Specialty claims volume increased in Q3 2021 vs previous Quarters
- SJVIA's specialty plan cost is roughly 4-9% higher than the EmpiRx BOB national average range (30% - 35%)

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail GDR	84.29%	86.60%	85.48%	83.77%	81.77%	84.03%	82.76%	82.00%
Retail90 GDR	87.74%	88.32%	88.11%	88.15%	88.42%	88.72%	89.09%	88.62%
Mail GDR	82.88%	80.65%	87.18%	82.88%	83.57%	88.94%	87.83%	86.39%




- Overall, the generic dispensing rate is trending well for SJVIA

*Excludes specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Plan Cost	\$3,009,806	\$3,318,620	\$3,153,231	\$3,239,486	\$3,167,162	\$3,011,302	\$3,026,653	\$3,129,386
Mail Plan Cost	\$51,260	\$50,172	\$38,441	\$50,778	\$42,925	\$39,955	\$42,883	\$41,833
Retail Plan Cost %	98.33%	98.51%	98.80%	98.46%	98.66%	98.69%	98.60%	98.68%
Mail Plan Cost %	1.67%	1.49%	1.20%	1.54%	1.34%	1.31%	1.40%	1.32%



- Mail plan cost has continued to stay below the 2% range in 2021, while retail plan cost has consistently stayed above 98% of plan costs.
- The mail channel accounts for just 1.32% of the plan spend in Q3 of 2021.

*Excludes specialty

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: SJVIA

Top Drugs By Ingredient Cost
Based on Paid Date: 01/01/2021-09/30/2021

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Specialty Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	94	17	\$697,541.19	2,632	\$7,420.65	\$265.02
TRULICITY	ANTIDIABETICS	B	2	N	553	113	\$665,896.45	22,416	\$1,204.15	\$29.71
OZEMPIC	ANTIDIABETICS	B	2	N	312	91	\$379,513.94	13,572	\$1,216.39	\$27.96
TREMFYA	DERMATOLOGICALS	B	2	Y	29	9	\$354,282.85	1,512	\$12,216.65	\$234.31
JARDIANCE	ANTIDIABETICS	B	2	N	298	96	\$320,923.08	18,000	\$1,076.92	\$17.83
DUPIXENT	DERMATOLOGICALS	B	2	Y	96	15	\$314,157.96	2,632	\$3,272.48	\$119.36
JANUVIA	ANTIDIABETICS	B	2	N	329	107	\$309,929.04	19,188	\$942.03	\$16.15
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	17	2	\$262,889.36	510	\$15,464.08	\$515.47
FARXIGA	ANTIDIABETICS	B	2	N	258	78	\$262,818.44	15,148	\$1,018.68	\$17.35
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	40	7	\$256,832.04	1,120	\$6,420.80	\$229.31
TRIKAFTA	RESPIRATORY AGENTS - MISC.	B	2	Y	10	1	\$249,475.60	280	\$24,947.56	\$890.98
COSENTYX SENSOREADY PEN	DERMATOLOGICALS	B	3	Y	35	5	\$216,657.70	980	\$6,190.22	\$221.08
ELIQUIS	ANTICOAGULANTS	B	2	N	266	73	\$210,911.27	13,052	\$792.90	\$16.16
LATUDA	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	2	N	115	26	\$198,357.25	3,990	\$1,724.85	\$49.71
STELARA	DERMATOLOGICALS	B	2	Y	8	3	\$172,722.42	588	\$21,590.30	\$293.75
LANTUS SOLOSTAR	ANTIDIABETICS	B	2	N	282	89	\$168,063.86	14,088	\$595.97	\$11.93
ICLUSIG	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$146,732.12	240	\$18,341.52	\$611.38
XELJANZ XR	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	28	5	\$141,628.57	840	\$5,058.16	\$168.61
GENOTROPIN	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	2	Y	19	2	\$134,059.86	544	\$7,055.78	\$246.43
OTEZLA	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	32	6	\$126,026.97	960	\$3,938.34	\$131.28
HUMALOG	ANTIDIABETICS	B	2	N	89	33	\$124,653.36	4,299	\$1,400.60	\$29.00
XARELTO	ANTICOAGULANTS	B	2	N	121	42	\$119,242.83	7,278	\$985.48	\$16.38
TRINTELLIX	ANTIDEPRESSANTS	B	3	N	168	46	\$114,479.08	8,020	\$681.42	\$14.27
RYBELSUS	ANTIDIABETICS	B	2	N	79	34	\$111,408.54	4,080	\$1,410.23	\$27.31
VASCEPA	ANTIHYPERLIPIDEMICS	B	2	N	165	84	\$109,852.14	10,170	\$665.77	\$10.80

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: SJVIA

Top Drugs By Claim Count

Based on Paid Date: 01/01/2021-09/30/2021

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Specialty Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	2,296	857	\$79,526.30	163,800	\$34.64	\$0.49
LISINAPRIL	ANTHYPERTENSIVES	G	1	N	1,794	662	\$36,674.45	126,122	\$20.44	\$0.29
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	1,685	556	\$46,218.55	119,236	\$27.43	\$0.39
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	1,577	980	\$81,639.54	44,199	\$51.77	\$1.85
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	1,364	518	\$30,224.10	91,034	\$22.16	\$0.33
PFIZER-BIONTECH COVID-19	VACCINES	B	2	N	1,257	781	\$0.00	1,257	\$0.00	\$0.00
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	1,250	522	\$30,567.40	76,628	\$24.45	\$0.40
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	1,166	412	\$21,889.08	79,592	\$18.77	\$0.28
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	1,141	855	\$26,161.89	22,309	\$22.93	\$1.17
HYDROCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	G	1	N	1,045	491	\$41,611.81	19,415	\$39.82	\$2.14
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	1,042	310	\$76,954.78	54,674	\$73.85	\$1.41
LOSARTAN POTASSIUM	ANTHYPERTENSIVES	G	1	N	1,005	361	\$43,221.29	72,236	\$43.01	\$0.60
GABAPENTIN	ANTICONVULSANTS	G	1	N	995	384	\$36,679.07	42,190	\$36.86	\$0.87
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	896	315	\$47,607.41	64,702	\$53.13	\$0.74
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	878	374	\$22,678.03	49,273	\$25.83	\$0.46
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	806	272	\$18,779.68	42,802	\$23.30	\$0.44
VITAMIN D	VITAMINS	G	1	N	802	394	\$7,558.05	46,743	\$9.42	\$0.16
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	800	293	\$9,750.97	54,611	\$12.19	\$0.18
ROSUVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	788	295	\$31,576.64	56,042	\$40.07	\$0.56
AMOXICILLIN	PENICILLINS	G	1	N	740	665	\$6,291.68	6,144	\$8.50	\$1.02
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	731	498	\$25,185.85	32,210	\$34.45	\$0.78
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	723	306	\$20,368.50	46,274	\$28.17	\$0.44
ALPRAZOLAM	ANTIANSXIETY AGENTS	G	1	N	707	245	\$11,120.38	18,501	\$15.73	\$0.60
AZITHROMYCIN	MACROLIDES	G	1	N	684	608	\$15,981.42	3,914	\$23.36	\$4.08
PREDNISONE	CORTICOSTEROIDS	G	1	N	678	484	\$6,269.59	10,838	\$9.25	\$0.58

Quarterly Key Pharmacy Benefit Metrics

Specialty Drug Oversight

- The management of specialty drugs is complex, as are the conditions that specialty drugs treat. With recent advances in drug therapies, patients with complex conditions now have better options to manage their conditions. While plan sponsors like the SJVIA recognize the value of these medications to their members and want to provide best-in-class drug benefits, the cost management of these drugs requires utilization management and benefit design strategies.
- Strategies implemented for the SJVIA include:
 - Prior authorization/clinical review
 - Specialty pharmacy channel management
 - Ongoing formulary review for the most cost and clinically effective medications
 - Manufacturer assistance when available

Quarterly Key Pharmacy Benefit Metrics

Rebates & Clinical Management Savings

- Rebates:
 - Q1 2021 net rebate amount that was paid out to SJVIA was \$663,828.00
 - Q2 2021 Estimated net rebate amount is \$694,892.00

*Beginning with the fourth quarter of 2020, Rebates will be paid within 120 days at the end of the applicable quarter.
- Clinical savings guarantee for 18 Months: \$1,500,000
 - Prorated Clinical Guarantee (Q3 2020-Q2 2021): \$1,000,000.00
 - Q3 2020- Q2 2021 Estimated Clinical Savings Performance: \$3,029,408.00

*Keenan performs a clinical savings financial audit and presents the final report to the SJVIA upon completion.

Appendix

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Tulare)

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Gross Cost	\$2,020,551	\$2,150,586	\$2,111,798	\$2,103,411	\$2,126,190	\$1,964,808	\$2,236,357	\$2,340,728
Plan Cost	\$1,859,979	\$1,968,537	\$1,939,264	\$1,929,831	\$1,954,639	\$1,791,328	\$2,057,651	\$2,160,996
Member Cost	\$160,572	\$182,049	\$172,533	\$173,579	\$171,551	\$173,480	\$178,705	\$179,732



This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
 These represent total dollars spent for all products, including specialty drugs

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Fresno)

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Gross Cost	\$2,809,426	\$3,166,647	\$3,041,764	\$3,042,464	\$3,023,845	\$2,864,648	\$3,227,408	\$3,343,256
Plan Cost	\$2,600,251	\$2,922,097	\$2,824,414	\$2,831,636	\$2,814,888	\$2,652,050	\$3,014,890	\$3,123,415
Member Cost	\$209,175	\$244,550	\$217,350	\$210,828	\$208,956	\$212,598	\$212,518	\$219,841




This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
 These represent total dollars spent for all products, including specialty drugs

Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Tulare)


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Brand	\$444,835	\$473,482	\$471,239	\$485,916	\$500,819	\$449,914	\$442,516	\$478,592
Retail Generic	\$264,207	\$292,110	\$264,094	\$250,354	\$225,339	\$209,849	\$205,842	\$212,981
Retail90 Brand	\$321,262	\$335,014	\$343,733	\$343,469	\$347,451	\$317,449	\$361,520	\$369,584
Retail90 Generic	\$135,880	\$141,460	\$154,534	\$178,844	\$174,057	\$166,146	\$174,493	\$164,873
Mail Brand	\$19,733	\$21,121	\$16,314	\$20,701	\$19,965	\$16,684	\$17,054	\$20,737
Mail Generic	\$11,265	\$9,610	\$8,881	\$13,234	\$13,230	\$10,747	\$14,971	\$11,599
Specialty	\$662,797	\$695,741	\$680,470	\$637,313	\$673,779	\$620,539	\$841,255	\$902,631



Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Fresno)


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Brand	\$717,177	\$777,547	\$715,434	\$718,758	\$713,086	\$698,442	\$688,092	\$714,659
Retail Generic	\$404,658	\$474,932	\$411,102	\$410,811	\$343,292	\$325,526	\$310,554	\$319,035
Retail90 Brand	\$495,475	\$566,030	\$542,467	\$571,612	\$581,409	\$568,006	\$576,610	\$608,728
Retail90 Generic	\$218,620	\$255,489	\$250,628	\$279,722	\$281,710	\$275,972	\$267,025	\$260,935
Mail Brand	\$15,952	\$14,257	\$6,313	\$11,404	\$2,857	\$5,411	\$4,482	\$3,726
Mail Generic	\$4,192	\$5,185	\$6,933	\$5,438	\$6,874	\$7,113	\$6,375	\$5,771
Specialty	\$744,176	\$828,659	\$891,537	\$833,891	\$885,661	\$771,582	\$1,161,751	\$1,210,561



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Tulare)


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Brand	1,284	1,207	1,111	1,290	1,367	1,148	1,184	1,322
Retail Generic	7,788	8,740	7,108	7,440	7,312	6,864	7,029	7,003
Retail90 Brand	346	343	358	358	343	307	336	347
Retail90 Generic	2,570	2,753	2,854	2,905	2,876	2,870	2,913	2,885
Mail Brand	23	22	18	22	26	15	17	18
Mail Generic	128	120	121	130	124	118	131	108
Specialty	198	198	200	188	197	190	208	223



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Fresno)


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Brand	1,995	1,879	1,608	1,951	2,167	1,771	2,045	2,131
Retail Generic	9,738	11,178	8,898	9,284	8,544	8,500	8,467	8,727
Retail90 Brand	565	607	590	609	599	599	555	588
Retail90 Generic	3,955	4,425	4,171	4,291	4,315	4,253	4,362	4,394
Mail Brand	15	20	12	16	9	8	11	8
Mail Generic	53	55	83	54	54	67	71	57
Specialty	281	297	320	303	310	287	331	355



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Tulare)


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Specialty Plan Cost	\$662,797	\$695,741	\$680,470	\$637,313	\$673,779	\$620,539	\$841,255	\$902,631
Total Plan Cost	\$1,859,979	\$1,968,537	\$1,939,264	\$1,929,831	\$1,954,639	\$1,791,328	\$2,057,651	\$2,160,996
Specialty Plan Cost %	35.63%	35.34%	35.09%	33.02%	34.47%	34.64%	40.88%	41.77%



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Fresno)


Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Specialty Plan Cost	\$744,176	\$828,659	\$891,537	\$833,891	\$885,661	\$771,582	\$1,161,751	\$1,210,561
Total Plan Cost	\$2,600,251	\$2,922,097	\$2,824,414	\$2,831,636	\$2,814,888	\$2,652,050	\$3,014,890	\$3,123,415
Specialty Plan Cost %	28.62%	28.36%	31.57%	29.45%	31.46%	29.09%	38.53%	38.76%



Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Tulare)

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail GDR	85.85%	87.87%	86.48%	85.22%	84.25%	85.67%	85.58%	84.12%
Retail90 GDR	88.13%	88.92%	88.85%	89.03%	89.34%	90.34%	89.66%	89.26%
Mail GDR	84.77%	84.51%	87.05%	85.53%	82.67%	88.72%	88.51%	85.71%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Fresno)

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail GDR	83.00%	85.61%	84.69%	82.63%	79.77%	82.76%	80.55%	80.37%
Retail90 GDR	87.50%	87.94%	87.61%	87.57%	87.81%	87.65%	88.71%	88.20%
Mail GDR	77.94%	73.33%	87.37%	77.14%	85.71%	89.33%	86.59%	87.69%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Tulare)

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Plan Cost	\$1,166,184	\$1,242,066	\$1,233,600	\$1,258,583	\$1,247,666	\$1,143,357	\$1,184,371	\$1,226,030
Mail Plan Cost	\$30,998	\$30,731	\$25,195	\$33,935	\$33,194	\$27,432	\$32,025	\$32,336
Retail Plan Cost %	97.41%	97.59%	98.00%	97.37%	97.41%	97.66%	97.37%	97.43%
Mail Plan Cost %	2.59%	2.41%	2.00%	2.63%	2.59%	2.34%	2.63%	2.57%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Fresno)

Category	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Retail Plan Cost	\$1,835,931	\$2,073,997	\$1,919,630	\$1,980,903	\$1,919,496	\$1,867,945	\$1,842,282	\$1,903,357
Mail Plan Cost	\$20,144	\$19,442	\$13,246	\$16,842	\$9,731	\$12,523	\$10,857	\$9,497
Retail Plan Cost %	98.91%	99.07%	99.31%	99.16%	99.50%	99.33%	99.41%	99.50%
Mail Plan Cost %	1.09%	0.93%	0.69%	0.84%	0.50%	0.67%	0.59%	0.50%



Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Tulare

Top Drugs By Ingredient Cost: Tulare

Based on Paid Date: 01/01/2021-09/30/2021

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	50	9	\$368,813.59	1,400	\$7,376.27	\$263.44
TRIKAFTA	RESPIRATORY AGENTS - MISC.	B	2	Y	10	1	\$249,475.60	280	\$24,947.56	\$890.98
TRULICITY	ANTIDIABETICS	B	2	N	188	42	\$234,158.00	7,948	\$1,245.52	\$29.46
OZEMPIC	ANTIDIABETICS	B	2	N	151	39	\$178,538.94	6,080	\$1,182.38	\$29.36
JANUVIA	ANTIDIABETICS	B	2	N	174	49	\$148,730.49	9,164	\$854.77	\$16.23
ICLUSIG	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$146,732.12	240	\$18,341.52	\$611.38
JARDIANCE	ANTIDIABETICS	B	2	N	138	40	\$134,473.95	7,500	\$974.45	\$17.93
ELIQUIS	ANTICOAGULANTS	B	2	N	158	41	\$131,990.75	8,277	\$835.38	\$15.95
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$123,712.64	240	\$15,464.08	\$515.47
TREMFYA	DERMATOLOGICALS	B	2	Y	9	4	\$110,167.21	448	\$12,240.80	\$245.91
FARXIGA	ANTIDIABETICS	B	2	N	117	31	\$107,785.23	6,180	\$921.24	\$17.44
XELJANZ XR	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	21	4	\$106,424.87	630	\$5,067.85	\$168.93
STELARA	DERMATOLOGICALS	B	2	Y	5	2	\$98,698.53	420	\$19,739.71	\$235.00
XTANDI	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	7	1	\$89,710.81	210	\$12,815.83	\$427.19
GILENYA	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	B	2	Y	9	2	\$83,931.83	270	\$9,325.76	\$310.86
XARELTO	ANTICOAGULANTS	B	2	N	75	25	\$79,970.10	4,941	\$1,066.27	\$16.19
ZYTIGA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	7	1	\$79,562.35	210	\$11,366.05	\$378.87
VUMERITY	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	B	2	Y	9	1	\$69,762.33	270	\$7,751.37	\$258.38
LANTUS SOLOSTAR	ANTIDIABETICS	B	2	N	118	36	\$69,369.36	5,452	\$587.88	\$12.72
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	11	2	\$66,686.52	308	\$6,062.41	\$216.51
TRINTELLIX	ANTIDEPRESSANTS	B	3	N	91	27	\$60,275.12	4,330	\$662.36	\$13.92
RINVOQ	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	11	2	\$59,247.21	330	\$5,386.11	\$179.54
DUPIXENT	DERMATOLOGICALS	B	2	Y	18	2	\$58,911.68	504	\$3,272.87	\$116.89
RYBELSUS	ANTIDIABETICS	B	2	N	44	13	\$55,161.42	2,010	\$1,253.67	\$27.44
HUMALOG	ANTIDIABETICS	B	2	N	46	16	\$54,802.60	2,166	\$1,191.36	\$25.30

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Tulare

Top Drugs By Claim Count: Tulare

Based on Paid Date: 01/01/2021-09/30/2021

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	959	326	\$30,026.59	62,441	\$31.31	\$0.48
LISINAPRIL	ANTHYPERTENSIVES	G	1	N	772	267	\$14,600.81	49,978	\$18.91	\$0.29
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	760	232	\$19,272.50	49,095	\$25.36	\$0.39
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	536	206	\$12,600.81	31,933	\$23.51	\$0.39
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	522	329	\$27,917.96	15,336	\$53.48	\$1.82
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	515	171	\$9,185.81	33,032	\$17.84	\$0.28
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	505	190	\$10,224.70	32,810	\$20.25	\$0.31
LOSARTAN POTASSIUM	ANTHYPERTENSIVES	G	1	N	491	163	\$20,152.03	33,139	\$41.04	\$0.61
HYDROCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	G	1	N	488	229	\$19,407.64	8,793	\$39.77	\$2.21
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	487	203	\$12,200.49	26,524	\$25.05	\$0.46
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	482	140	\$29,132.90	23,435	\$60.44	\$1.24
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	408	142	\$4,936.05	25,859	\$12.10	\$0.19
GABAPENTIN	ANTICONVULSANTS	G	1	N	405	158	\$13,734.57	17,567	\$33.91	\$0.78
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	398	317	\$8,237.03	6,910	\$20.70	\$1.19
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	395	133	\$19,289.76	26,776	\$48.83	\$0.72
PFIZER-BIONTECH COVID-19	VACCINES	B	2	N	366	253	\$0.00	366	\$0.00	\$0.00
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	363	121	\$8,296.01	18,695	\$22.85	\$0.44
ALPRAZOLAM	ANTIANSXIETY AGENTS	G	1	N	347	140	\$5,699.03	9,170	\$16.42	\$0.62
PREDNISONE	CORTICOSTEROIDS	G	1	N	341	227	\$3,506.86	6,053	\$10.28	\$0.58
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	338	130	\$8,372.91	19,094	\$24.77	\$0.44
VITAMIN D	VITAMINS	G	1	N	333	157	\$3,351.23	17,974	\$10.06	\$0.19
ROSUVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	317	110	\$11,920.69	21,254	\$37.60	\$0.56
AMOXICILLIN	PENICILLINS	G	1	N	304	266	\$2,577.37	2,469	\$8.48	\$1.04
AZITHROMYCIN	MACROLIDES	G	1	N	301	265	\$7,127.92	1,868	\$23.68	\$3.82
SERTRALINE HCL	ANTIDEPRESSANTS	G	1	N	294	114	\$5,682.06	13,909	\$19.33	\$0.41

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Fresno

Top Drugs By Ingredient Cost: Fresno
Based on Paid Date: 01/01/2021-09/30/2021

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
TRULICITY	ANTIDIABETICS	B	2	N	365	71	\$431,738.45	14,468	\$1,182.85	\$29.84
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	44	8	\$328,727.60	1,232	\$7,471.08	\$266.82
DUPIXENT	DERMATOLOGICALS	B	2	Y	78	13	\$255,246.28	2,128	\$3,272.39	\$119.95
TREMFYA	DERMATOLOGICALS	B	2	Y	20	5	\$244,115.64	1,064	\$12,205.78	\$229.43
OZEMPIC	ANTIDIABETICS	B	2	N	161	52	\$200,975.00	7,492	\$1,248.29	\$26.83
COSENTYX SENSOREADY PEN	DERMATOLOGICALS	B	3	Y	32	4	\$198,087.04	896	\$6,190.22	\$221.08
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	29	5	\$190,145.52	812	\$6,556.74	\$234.17
JARDIANCE	ANTIDIABETICS	B	2	N	160	56	\$186,449.13	10,500	\$1,165.31	\$17.76
LATUDA	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	2	N	101	21	\$179,130.63	3,570	\$1,773.57	\$50.18
JANUVIA	ANTIDIABETICS	B	2	N	155	58	\$161,198.55	10,024	\$1,039.99	\$16.08
FARXIGA	ANTIDIABETICS	B	2	N	141	47	\$155,033.21	8,968	\$1,099.53	\$17.29
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	9	1	\$139,176.72	270	\$15,464.08	\$515.47
GENOTROPIN	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	2	Y	19	2	\$134,059.86	544	\$7,055.78	\$246.43
BIKTARVY	ANTIVIRALS	B	2	Y	29	5	\$101,201.77	870	\$3,489.72	\$116.32
LANTUS SOLOSTAR	ANTIDIABETICS	B	2	N	164	53	\$98,694.50	8,636	\$601.80	\$11.43
OTEZLA	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	23	4	\$90,697.54	690	\$3,943.37	\$131.45
VASCEPA	ANTIHYPERTENSIVES	B	2	N	127	68	\$88,711.43	8,130	\$698.52	\$10.91
IMBRUVICA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	6	1	\$87,229.92	168	\$14,538.32	\$519.23
JYNARQUE	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	3	Y	5	1	\$83,919.65	140	\$16,783.93	\$599.43
REXULTI	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	3	N	53	14	\$81,209.13	1,950	\$1,532.25	\$41.65
ELIQUIS	ANTICOAGULANTS	B	2	N	108	32	\$78,920.52	4,775	\$730.75	\$16.53
STELARA	DERMATOLOGICALS	B	2	Y	3	1	\$74,023.89	168	\$24,674.63	\$440.62
WIXELA INHUB	ANTI-ASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	149	73	\$72,779.53	6,510	\$488.45	\$11.18
INVOKANA	ANTIDIABETICS	B	2	N	70	19	\$70,972.97	4,020	\$1,013.90	\$17.65
HUMALOG	ANTIDIABETICS	B	2	N	43	17	\$69,850.76	2,133	\$1,624.44	\$32.75

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Fresno

Top Drugs By Claim Count: Fresno
Based on Paid Date: 01/01/2021-09/30/2021

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	1,337	531	\$49,499.71	101,359	\$37.02	\$0.49
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	1,055	651	\$53,721.58	28,863	\$50.92	\$1.86
LISINAPRIL	ANTIHYPERTENSIVES	G	1	N	1,022	395	\$22,073.64	76,144	\$21.60	\$0.29
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	925	324	\$26,946.05	70,141	\$29.13	\$0.38
PFIZER-BIONTECH COVID-19	VACCINES	B	2	N	891	528	\$0.00	891	\$0.00	\$0.00
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	859	328	\$19,999.40	58,224	\$23.28	\$0.34
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	743	538	\$17,924.86	15,399	\$24.12	\$1.16
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	714	316	\$17,966.59	44,695	\$25.16	\$0.40
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	651	241	\$12,703.27	46,560	\$19.51	\$0.27
GABAPENTIN	ANTICONVULSANTS	G	1	N	590	226	\$22,944.50	24,623	\$38.89	\$0.93
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	560	170	\$47,821.88	31,239	\$85.40	\$1.53
HYDROCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	G	1	N	557	262	\$22,204.17	10,622	\$39.86	\$2.09
LOSARTAN POTASSIUM	ANTIHYPERTENSIVES	G	1	N	514	198	\$23,069.26	39,097	\$44.88	\$0.59
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	501	182	\$28,317.65	37,926	\$56.52	\$0.75
ROSUVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	471	185	\$19,655.95	34,788	\$41.73	\$0.57
VITAMIN D	VITAMINS	G	1	N	469	237	\$4,206.82	28,769	\$8.97	\$0.15
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	452	306	\$15,251.32	19,700	\$33.74	\$0.77
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	443	151	\$10,483.67	24,107	\$23.67	\$0.43
AMOXICILLIN	PENICILLINS	G	1	N	436	399	\$3,714.31	3,675	\$8.52	\$1.01
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	392	151	\$4,814.92	28,752	\$12.28	\$0.17
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	391	171	\$10,477.54	22,749	\$26.80	\$0.46
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	385	176	\$11,995.59	27,180	\$31.16	\$0.44
AZITHROMYCIN	MACROLIDES	G	1	N	383	343	\$8,853.50	2,046	\$23.12	\$4.33
CYCLOBENZAPRINE HYDROCHLO	MUSCULOSKELETAL THERAPY AGENTS	G	1	N	368	227	\$5,546.50	8,496	\$15.07	\$0.65
TRULICITY	ANTIDIABETICS	B	2	N	365	71	\$431,738.45	14,468	\$1,182.85	\$29.84